Docetaxel

Chemodex
Product Code: CDX-D0371
Supplier: Chemodex
CodeSizePrice
CDX-D0371-M0055 mg£48.00
Quantity:
CDX-D0371-M02525 mg£121.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
-20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
Taxotere®; NSC 628503; RP 56976; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
Appearance:
White to off-white powder.
CAS:
114977-28-5
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChiKey:
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Long Description:
Chemical. CAS: 114977-28-5. Formula: C43H53NO14. MW: 807.88. Synthetic. Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the beta?tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.
MDL:
MFCD00800737
Molecular Formula:
C43H53NO14
Molecular Weight:
807.88
Package Type:
Vial
Product Description:
Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the beta?tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.
Purity:
>97% (HPLC)
SMILES:
CC(C)(OC(N[C@H]([C@H](C(O[C@H]1C[C@@]([C@H]([C@@H]([C@@]2(C([C@@H](C3=C1C)O)=O)C)[C@]4([C@@H](C[C@@H]2O)OC4)OC(C)=O)OC(C5=CC=CC=C5)=O)(C3(C)C)O)=O)O)C6=CC=CC=C6)=O)C
Solubility Chemicals:
Soluble in DMSO or ethanol.
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

(1) M.C. Bissery, et al.; Cancer Res. 51, 4845 (1991) | (2) R. Bruno & G.J. Sanderink; Cancer Surv. 17, 305 (1993) (Review) | (3) K. Gelmon; Lancet 344, 1267 (1994) (Review) | (4) M.E. Trudeau; Can. J. Oncol. 6, 443 (1996) (Review) | (5) I.A. Avramis, et al.; Anticancer Res. 21, 2281 (2001) | (6) M. Aapro & E. Rowinsky; Anticancer Drugs 12, S1 (2001) (Review) | (7) P.B. Cassidy, et al.; Clin. Cancer Res. 8, 846 (2002) | (8) M.S. Si, et al.; Invest. New Drugs 21, 281 (2003) | (9) B. Ramaswamy & S. Puhalla; Drugs Today 42, 265 (2006) (Review) | (10) H. Hernandez-Vargas, et al.; Cell Cycle 6, 780 (2007) (Review) | (11) H. Ching-Hsia, et al.; Toxicol. Sci. 145, 59 (2015)

Related Products

Product NameProduct CodeSupplier 
BromobutideCDX-B0124Chemodex Summary Details
FlumetsulamCDX-F0080Chemodex Summary Details
Flupyrsulfuron-methyl sodiumCDX-F0083Chemodex Summary Details